People | April 29, 2026
NADMED Limited appoints James Lee as CEO to drive global expansion
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The submission is backed by positive results from the Phase 3 AFFIRM study
Subscribe To Our Newsletter & Stay Updated
